NAD+ Boosters: The Biomarker Moves Reliably. Nothing Downstream Does.

The case for NAD+ supplementation rests on three links: NAD+ declines with age, restoring it should restore mitochondrial function, and that should change how you feel. The first link is real. The trials sit on the second, and they are unusually consistent.

The biomarker goes up. Insulin sensitivity does not change. Muscle function does not change. Mitochondrial capacity does not change. A 2025 meta-analysis of ten randomised controlled trials found no statistically significant effect on any outcome examined. NAD+ sits alongside the immune support and longevity peptides category and inside our overview of peptides for energy and mitochondrial function, where it is the best-tested member and the one with the clearest answer.

Do NAD+ boosters actually raise NAD+?

Yes — NAD+ boosters raise blood NAD+ reliably, and this is the part of the claim that holds. Trammell et al. 2016 established that oral nicotinamide riboside raises blood NAD+ in humans dose-dependently, up to 2.7-fold. Martens et al. 2018 confirmed it in middle-aged and older adults, where NAD+ rose about 60%. These are randomised, placebo-controlled trials with objective measurements. The chain of reasoning breaks further down, not here.

The NAD+ literature is better than most of what this site covers, and that is the point. These are not underpowered pilot studies or open-label observations. They are properly designed trials with objective endpoints, which is exactly what makes the pattern in them so informative.

Does raising NAD+ change anything downstream?

No. Across the trials run so far, raising NAD+ has not moved insulin sensitivity, muscle function or mitochondrial capacity. Martens 2018 found all physiological endpoints null despite a 60% NAD+ rise. Dollerup 2018 gave 2000 mg/day of nicotinamide riboside for 12 weeks to 40 obese insulin-resistant men and found nothing. Remie 2020 was null. Prokopidis 2025, a meta-analysis of 10 randomised controlled trials, found all outcomes non-significant.

Dollerup deserves the most attention. Forty men with obesity and insulin resistance — the population most likely to benefit — received two grams a day of nicotinamide riboside for twelve weeks, a dose far above typical consumer supplementation, in a proper randomised placebo-controlled design, with insulin sensitivity measured by clamp. It found nothing.

That is not an underpowered study failing to detect a small effect. It is a high dose, in a responsive population, over a meaningful duration, with a gold-standard measurement, returning null.

The field's own assessment matches. Damgaard and Treebak, writing in Science Advances in 2023, reviewed twenty-five human studies of NAD+ precursors and concluded there is "an unfortunate tendency in the literature to exaggerate the importance and robustness of reported effects." That sentence comes from inside the field, not from critics of it.

Is NAD+ a peptide?

No. NAD+ is nicotinamide adenine dinucleotide, formula C₂₁H₂₇N₇O₁₄P₂, molecular weight 663.4 g/mol — a dinucleotide coenzyme with no amino acids and no peptide bonds. It sits in peptide shops and gets discussed as though it were one, but it is two nucleotides joined through their phosphate groups. The precursors sold alongside it, nicotinamide riboside and nicotinamide mononucleotide, are small molecules, not peptides either. That distinction changes how a certificate of analysis for it should be read.

The practical consequence is that the identity and purity testing conventions this platform applies to peptides do not transfer cleanly. HPLC still works, but the degradation chemistry is different, the relevant impurities are different, and "peptide purity" language on a certificate of analysis for NAD+ suggests the vendor has copied a template rather than tested the product in front of them. Vendor listings sit on the NAD+ compound page.

NR and NMN reach NAD+ the same way anything else does: the body converts them through the salvage pathway. That matters more than it sounds, because it is also what happens to infused NAD+.

Is intravenous NAD+ better than oral?

No — the head-to-head comparison went the other way. IV NAD+ performed worse than IV nicotinamide riboside, with more adverse events and infusion times two to four times longer. The pharmacology explains it: NAD+ is a large, charged dinucleotide that does not cross cell membranes well, so infusing it does not deliver it into cells. It is largely degraded extracellularly and resynthesised through the same salvage pathway an oral precursor uses.

Intravenous NAD+ is marketed as the serious version — bypassing digestion, delivering the coenzyme directly. Clinics charge accordingly, and the infusions run for hours. The direct route is not direct.

The infusion time is worth reading correctly too. It is a tolerability constraint, not a sign of thoroughness. Infusing NAD+ faster causes flushing, chest tightness and nausea, which is why the drip is slowed.

What happened in the October 2025 NAD+ injection recall?

On 21 October 2025, FDA classified a Class I recall of NAD+ injection produced by GenoGenix, for endotoxin contamination. Class I is FDA's most serious recall category, reserved for products where there is a reasonable probability that use will cause serious adverse health consequences or death. Endotoxin — bacterial lipopolysaccharide — causes fever, hypotension and, at sufficient dose in an intravenous product, septic shock. It survives sterilisation.

That last point is the one people miss. Filtering out bacteria does not remove what the bacteria left behind, which is why endotoxin testing by LAL assay is not an optional extra on any injectable. Across this market, the endotoxin field on certificates of analysis is blank far more often than not. See endotoxin testing and LAL assay interpretation and GMP versus non-GMP manufacturing.

This is the specific risk of injectable products made outside pharmaceutical-grade manufacturing, and it is the only documented harm in the NAD+ category.

Is NMN still excluded from the dietary supplement definition?

No — that exclusion was reversed on 29 September 2025. For several years the settled story was that FDA had excluded nicotinamide mononucleotide from the dietary supplement definition, because it had been authorised for investigation as a new drug before being marketed as a supplement. Most content still says this. It is out of date: NMN's regulatory position changed, and any article, vendor page or forum post describing it as barred from the supplement market is wrong.

This one matters beyond NMN. It is a live example of why regulatory claims need dating: a confident, correct-in-2024 statement became a false statement in September 2025, and content that was never updated is now misinforming readers. Our FDA peptide regulation timeline tracks these changes, and are peptides legal covers status by country.

On WADA: NAD+ and its precursors are not on the 2026 Prohibited List.

Which NAD+ claims survive the trial record?

Two of nine. Of the nine claims routinely made for NAD+ boosters, only the age-related decline and the ability of oral nicotinamide riboside to raise blood NAD+ hold up — and the second is a biomarker, not a benefit. Three are refuted by randomised trials: insulin sensitivity, mitochondrial function and physical performance. One is contradicted by head-to-head data, two are false as stated, and one, anti-aging, has never been measured.

Note what the verdict column does not contain: an "unknown" row for efficacy. On most compounds this site covers, efficacy is unknown because nobody looked. Here it was measured, repeatedly.

Why does the NAD+ price page show zero shops in stock?

The NAD+ price page shows zero shops with product in stock at verification (August 2026), and the data cannot tell us why. The Purity Index records NAD+ at 99.07 across 306 recency-weighted tests (verified August 2026), against a platform composite of 99.50. A compound with 306 tests on file and no current inventory anywhere means vendors were selling it, testing it, and have stopped listing it.

Whether that reflects the October 2025 Class I recall, supply disruption, or shifting demand, we cannot say from the data. But a category with extensive historical testing and no current supply is a category in transition, and unusually available inventory during a market-wide gap deserves more scepticism than usual, not less. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), weighting community reviews and independently verified purity equally, at 50% each, in every trust score.

Note the ordering. On most compounds this table starts with mass spectrometry. Here it starts with endotoxin, because that is the risk that produced an actual Class I recall in this specific product category ten months ago. Independent results sit in the lab test database, and vendor-level scores in community-verified shop reviews.

How do NAD+ boosters compare with the other mitochondrial compounds?

NAD+ boosters are, by a wide margin, the best-studied category in this group — many well-conducted randomised trials, in which the biomarker rises reliably and downstream outcomes come back null. SS-31 ran four or more phase 2 and phase 3 trials, missed most primaries, and holds a narrow accelerated approval. MOTS-c has one recruiting trial and no results. FOXO4-DRI has never been tested in a human. That is exactly why the null result here is so useful.

When a hypothesis is tested properly and repeatedly and comes back null, that is far more informative than an untested compound's clean record. There is a version of the NAD+ story where the trials were too short, the endpoints wrong, or the populations too healthy — and that version is not unreasonable. But it now has to be argued against ten randomised controlled trials, a 2000 mg/day twelve-week study in the ideal population, and a meta-analysis finding nothing.

What trial would settle this?

The trial that would settle this is a randomised study running at least 12 months in older adults with documented NAD+ decline and functional impairment, measuring intracellular tissue NAD+ rather than blood, against a pre-registered functional primary endpoint. It would need a dose above 2000 mg/day or a different delivery route, since 2000 mg for 12 weeks already returned null, and it would have to address the Prokopidis meta-analysis of ten RCTs directly.

The fourth row is the most interesting unresolved question in this field. Blood NAD+ is a convenient measurement, and it is not obviously the relevant one. If oral precursors raise circulating NAD+ without raising it inside muscle and brain mitochondria, that would explain the entire biomarker-moves-function-doesn't pattern — and it would point at delivery, not the hypothesis, as the failure.

Frequently Asked Questions

Does NAD+ supplementation raise NAD+ levels?

Yes, reliably. Oral nicotinamide riboside raises blood NAD+ dose-dependently — up to 2.7-fold in Trammell 2016, about 60% in Martens 2018. This part of the claim is solid.

Does that translate into any benefit?

Not in the trials conducted so far. Martens 2018 found all physiological endpoints null despite a 60% NAD+ rise. Dollerup 2018 gave 2000 mg/day for 12 weeks to insulin-resistant men and found nothing. Remie 2020 was null. A 2025 meta-analysis of ten RCTs found no significant effect on any outcome.

Is intravenous NAD+ better than oral?

The comparison data says no. IV NAD+ performed worse than IV nicotinamide riboside, with more adverse events and infusion times two to four times longer. NAD+ is a large charged molecule that does not readily enter cells; infusing it does not bypass the salvage pathway.

Is injectable NAD+ safe?

FDA classified a Class I recall of GenoGenix NAD+ injection for endotoxin contamination on 21 October 2025. Class I is the most serious recall category. Anyone considering an injectable NAD+ product should require a batch-specific LAL endotoxin result.

Is NMN still banned as a supplement?

No. The FDA exclusion of NMN from the dietary supplement definition was reversed on 29 September 2025. Content stating otherwise is out of date.

Is NAD+ a peptide?

No. It is a dinucleotide coenzyme — no amino acids, no peptide bonds. It is sold alongside peptides but belongs to a different chemical class, and certificates of analysis using peptide-purity language for it should be read sceptically.

NAD+ boosters are the most rigorously tested category this site covers, and the results are the most consistently negative. That combination is uncomfortable, and it should be, because it cuts against the usual pattern here. Most of what gets sold in this market fails for lack of evidence. NAD+ has evidence — good evidence, from randomised placebo-controlled trials with objective endpoints — and what that evidence shows is a biomarker that responds beautifully and a body that does not notice.

The underlying biology remains sound. NAD+ does decline with age, it is central to mitochondrial metabolism, and sirtuins and PARPs do depend on it. The open question is whether raising circulating levels raises the levels that matter, inside cells, in tissues, where the coenzyme does its work. Nobody has shown that it does, and the twelve-week 2000 mg trial suggests that if it happens, it is not enough to register as a change in how a body functions.

Meanwhile a Class I recall for endotoxin in an injectable version, and a supplement exclusion that reversed after most articles were written, mean the practical picture around this compound has moved more in the past year than the science has in a decade.

Browse the immune support and longevity peptides category, or our complete peptide guide with 118 compounds (verified August 2026). Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.